Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : The Microcap Kitchen: Stocks 5¢ to $5 -- Ignore unavailable to you. Want to Upgrade?

To: GARY P GROBBEL who wrote (17014)	1/16/2004 1:15:36 PM
From: Rick Buskey	Read Replies (1) \| Respond to of 120415

BIPH-posted at $1.03----------and in at $1.03 too.

To: GARY P GROBBEL who wrote (17014)	1/16/2004 2:12:02 PM
From: John F. Poteraske	Respond to of 120415

BIPH-Hey that filled the gap real nice on chart.

To: GARY P GROBBEL who wrote (17014)	1/17/2004 2:17:06 AM
From: John F. Poteraske	Respond to of 120415

BIPH-Some more News biz.yahoo.com Biophan Expands Rights with Nanotechnology Partner Friday January 16, 5:54 pm ET ROCHESTER, N.Y.--(BUSINESS WIRE)--Jan. 16, 2004--Biophan Technologies, Inc. (OTC BB: BIPH), an innovator, developer and marketer of advanced biomedical technology, today announced it has secured additional technology rights expanding its exclusive license for use of nanomagnetic particle and other technology. Michael Weiner, chief executive officer of Biophan, made the announcement. The technology rights are granted under an expanded license agreement executed on January 15, 2004 with Nanoset, LLC that increases Biophan's rights to technology that may be applied to medical devices and other uses. The expanded rights include the exclusive right to any technology that affects magnetic resonance imaging (MRI) safety or image compatibility or involves an implantable power system. Under the license agreement, Biophan currently has rights to two United States patents and twelve pending United States patent applications. In addition Nanoset has received an indication from the United States Patent Office of allowablity for many of the claims of a patent application that relates to the Nanoview technology previously announced. "It should be clear that Biophan is continuing to successfully implement its strategic plan of creating a very substantial and diversified biomedical portfolio," stated Mr. Weiner. "With these additional rights, we believe management and the board of directors have demonstrated our commitment to capitalize on these exciting nanotechnology and other technology markets." Mr. Weiner concluded by noting, "With the proceeds from our recent financing, Biophan is well fortified to compete in these fast moving markets. We are well positioned to exploit our current technology and acquire complementary technology." About Nanoset, LLC Nanoset, LLC, based in East Rochester, NY, develops nanomagnetic particle coatings. Nanoset's research and development has been conducted with Alfred University, a world leader in ceramics and thin-film coatings. Nanoset and Biophan are jointly developing technologies for the medical device industry. About Biophan Technologies, Inc. Biophan Technologies develops and markets cutting-edge technologies used to make biomedical devices--such as cardiac pacemakers, surgical and diagnostic tool--safe and compatible with magnetic resonance imaging (MRI) equipment and other sources of powerful magnetism or radio frequency signals. Committed to growth through innovation and developmental leadership, Biophan's management holds exclusive licenses for four issued U.S. patents and has filed 51 related patents that will help establish Biophan products as the standard of care in each of their markets. For more information, please visit www.biophan.com.